Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that TransMedics Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines. Specifically, the Company reported earnings per share (“EPS”) of $0.12, missing EPS expectations of $0.29 by nearly 60%. TransMedics also reported revenue of $108.8 million, falling short of analysts’ $115 million estimate. Following this news, TransMedics stock dropped over 24% in after-hours trading.
In order to be eligible to join the TMDX class action lawsuit, you must have incurred a loss on shares of TransMedics Group, Inc. purchased during the class period listed above.
TOP
